文献速递炎症性肠病

生物制剂和小分子药物在腔内克罗恩病诱导和维持缓解中的疗效:系统评价与网状Meta分析

Efficacy of biological therapies and small molecules in induction and maintenance of remission in luminal Crohn's disease: systematic review and network meta-analysis.
PubMed 文献 · Gut · 2022-07-30

该系统评价与网状Meta分析检索至2022年7月1日的文献,纳入25项诱导缓解试验(8720例患者)和15项维持缓解试验(4016例患者),评估生物制剂和小分子药物在腔内克罗恩病中诱导临床缓解、临床应答及维持临床缓解的疗效。基于未达到临床缓解,英夫利西单抗5 mg/kg排名第一(RR=0.67,95% CI 0.56至0.79,p评分0.95);瑞莎珠单抗600 mg在初治和经治患者中均排名第一;乌帕替尼30 mg每日一次在维持缓解中排名第一(RR=0.61,95% CI 0.52至0.72,p评分0.93)。

要点

  • 英夫利西单抗5 mg/kg在全部患者诱导缓解中排名第一(RR=0.67,95% CI 0.56至0.79)。
  • 瑞莎珠单抗600 mg在生物制剂初治和经治患者诱导缓解中均排名第一。
  • 乌帕替尼30 mg每日一次在维持缓解中排名第一(RR=0.61,95% CI 0.52至0.72)。

核心结论

  • 在网状Meta分析中,英夫利西单抗5 mg/kg在全部腔内克罗恩病患者诱导临床缓解中排名第一,但瑞莎珠单抗600 mg在生物制剂初治和经治患者中排名第一。
  • 乌帕替尼30 mg每日一次在维持缓解中排名第一。

研究设计与样本

  • 系统评价与网状Meta分析,检索文献至2022年7月1日,采用随机效应模型,以合并相对危险度(RR)及95%置信区间(CI)报告数据,并根据p评分对药物排序。
  • 诱导缓解试验25项(8720例患者),维持缓解试验15项(4016例患者)。

主要发现

  • 基于未达到临床缓解,英夫利西单抗5 mg/kg对比安慰剂排名第一(RR=0.67,95% CI 0.56至0.79,p评分0.95),瑞莎珠单抗600 mg第二,乌帕替尼45 mg每日一次第三。
  • 瑞莎珠单抗600 mg在生物制剂初治患者临床缓解中排名第一(RR=0.66,95% CI 0.52至0.85,p评分0.78),在生物制剂经治患者中亦排名第一(RR=0.74,95% CI 0.67至0.82,p评分0.92)。
  • 基于疾病活动复发,乌帕替尼30 mg每日一次排名第一(RR=0.61,95% CI 0.52至0.72,p评分0.93),阿达木单抗40 mg每周第二,英夫利西单抗10 mg/kg每8周第三。
  • 阿达木单抗40 mg每周在生物制剂初治患者中排名第一(RR=0.59,95% CI 0.48至0.73,p评分0.86),维得利珠单抗108 mg每2周在生物制剂经治患者中排名第一(RR=0.70,95% CI 0.57至0.86,p评分0.82)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: There are numerous biological therapies and small molecules licensed for luminal Crohn's disease (CD), but these are often studied in placebo-controlled trials, meaning relative efficacy is uncertain. We examined this in a network meta-analysis. DESIGN: We searched the literature to 1 July 2022, judging efficacy according to induction of clinical remission, clinical response and maintenance of clinical remission, and according to previous exposure or non-exposure to biologics. We used a random effects model and reported data as pooled relative risks (RRs) with 95% CIs, ranking drugs according to p-score. RESULTS: We identified 25 induction of remission trials (8720 patients). Based on failure to achieve clinical remission, infliximab 5 mg/kg ranked first versus placebo (RR=0.67, 95% CI 0.56 to 0.79, p-score 0.95), with risankizumab 600 mg second and upadacitinib 45 mg once daily third. However, risankizumab 600 mg ranked first for clinical remission in biologic-naïve (RR=0.66, 95% CI 0.52 to 0.85, p-score 0.78) and in biologic-exposed patients (RR=0.74, 95% CI 0.67 to 0.82, p-score 0.92). In 15 maintenance of remission trials (4016 patients), based on relapse of disease activity, upadacitinib 30 mg once daily ranked first (RR=0.61, 95% CI 0.52 to 0.72, p-score 0.93) with adalimumab 40 mg weekly second, and infliximab 10 mg/kg 8-weekly third. Adalimumab 40 mg weekly ranked first in biologic-naïve patients (RR=0.59, 95% CI 0.48 to 0.73, p-score 0.86), and vedolizumab 108 mg 2-weekly first in biologic-exposed (RR=0.70, 95% CI 0.57 to 0.86, p-score 0.82). CONCLUSION: In a network meta-analysis, infliximab 5 mg/kg ranked first for induction of clinical remission in all patients with luminal CD, but risankizumab 600 mg was first in biologic-naïve and biologic-exposed patients. Upadacitinib 30 mg once daily ranked first for maintenance of remission.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Barberio B, Gracie DJ, Black CJ, et al. Efficacy of biological therapies and small molecules in induction and maintenance of remission in luminal Crohn's disease: systematic review and network meta-analysis. Gut. 2022. PMID: 35907636. doi:10.1136/gutjnl-2022-328052

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。